Moomoo AIのまとめ
Intelligent Bio Solutions Inc. (INBS) reported its financial performance for the quarter ended December 31, 2023. The company saw an increase in revenue to $764,063, up from $356,679 in the same period last year, primarily due to the expansion of its customer base and entry into new markets. Cost of revenue also rose to $564,815, resulting in a gross profit of $199,248. Government support income decreased to $153,204. Operating expenses totaled $2,343,809, with selling, general and administrative expenses at $1,705,044, development and regulatory approval expenses at $348,452, and depreciation and amortization at $290,313. The company experienced a net loss of $1,969,641, an increase from the previous year's $420,600, attributed to the combined operations post-acquisition of IFP and the absence of a fair value gain recognized in the prior year. Other comprehensive...Show More
Intelligent Bio Solutions Inc. (INBS) reported its financial performance for the quarter ended December 31, 2023. The company saw an increase in revenue to $764,063, up from $356,679 in the same period last year, primarily due to the expansion of its customer base and entry into new markets. Cost of revenue also rose to $564,815, resulting in a gross profit of $199,248. Government support income decreased to $153,204. Operating expenses totaled $2,343,809, with selling, general and administrative expenses at $1,705,044, development and regulatory approval expenses at $348,452, and depreciation and amortization at $290,313. The company experienced a net loss of $1,969,641, an increase from the previous year's $420,600, attributed to the combined operations post-acquisition of IFP and the absence of a fair value gain recognized in the prior year. Other comprehensive income included a foreign currency translation gain of $75,133. The company's cash and cash equivalents stood at $1,119,004, with a working capital deficit of $2,238,430. INBS acknowledged the need to raise additional funds within the next 12 months to support its operations and maintain its going concern status. The company's internal control over financial reporting was deemed ineffective due to material weaknesses, and efforts are ongoing to remediate these issues. INBS also completed a reverse stock split to comply with Nasdaq's minimum bid price requirement.
Intelligent Bio Solutions Inc.（INBS）は、2023年12月31日に終了した四半期の財務パフォーマンスを報告しました。同社は、顧客基盤の拡大や新しい市場への参入により、売上高が356,679ドルから764,063ドルに増加しました。一方、原価も564,815ドルに上昇し、粗利益は199,248ドルとなりました。政府サポート収入は153,204ドルに減少しました。営業費用は2,343,809ドルで、うち販売、一般管理費用が1,705,044ドル、開発および規制承認費用が348,452ドル、減価償却費が290,313ドルでした。同社は、IFPの買収に伴う合併後の運用...すべて展開
Intelligent Bio Solutions Inc.（INBS）は、2023年12月31日に終了した四半期の財務パフォーマンスを報告しました。同社は、顧客基盤の拡大や新しい市場への参入により、売上高が356,679ドルから764,063ドルに増加しました。一方、原価も564,815ドルに上昇し、粗利益は199,248ドルとなりました。政府サポート収入は153,204ドルに減少しました。営業費用は2,343,809ドルで、うち販売、一般管理費用が1,705,044ドル、開発および規制承認費用が348,452ドル、減価償却費が290,313ドルでした。同社は、IFPの買収に伴う合併後の運用と、前年度に認識された公正価値利益の不在が原因で、1,969,641ドルの純損失を計上しました。その他の包括的利益には、為替差損益として75,133ドルの外貨換算損益が含まれています。同社の現金及び現金同等物は1,119,004ドル、運転資本の赤字は2,238,430ドルとなっています。INBSは、事業を支援し、持続的な事業継続の状態を維持するために、次の12か月以内に追加の資金調達が必要であることを認めています。また、同社の財務報告上の内部統制は、重大な弱点があると判断されており、これらの問題の是正に向けて取り組んでいます。INBSは、ナスダックの最低買気配価格要件に適合するために、株式の逆分割を完了しました。
役に立った
役に立たない